We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Detection of Lupus-Associated Kidney Disease

By Biotechdaily staff writers
Posted on 19 Nov 2007
High urinary levels of certain molecules might serve as biomarkers for a potentially life-shortening kidney ailment caused by the autoimmune disease lupus.

Lupus is a chronic autoimmune disease in which the immune system attacks the body's cells and tissues. More...
In a normal immune system, foreign intruders are recognized by special immune cells that produce antibodies. In patients with lupus, however, the antibodies created start to attack the body itself. When the antibodies attack the kidneys, nephritis occurs, often shortening a patient's life expectancy. The most reliable method currently available for monitoring renal disease in lupus patients is to measure the level of protein excreted in urine.

Dr. Chandra Mohan, professor of internal medicine at the University of Texas Southwestern Medical Center (Dallas TX, USA) and colleagues screened urine from mice with lupus nephritis for the presence of four compounds--VCAM-1 (vascular cell adhesion molecule-1), P-selection, TNFR-1, and CXCL 16. Previous research had suggested that these molecules are elevated in animal models of antibody-mediated nephritis. The team determined that the mice harbored increased levels of all four molecules in the urine, particularly at the peak of their lupus-associated kidney disease.

Dr. Mohan said, "Our studies suggest a quartet of molecules may have potential diagnostic significance. Given that early intervention in lupus nephritis is associated with better treatment outcome, it is imperative that disease activity in the kidney be diagnosed as early as possible.”

Further studies are in progress to ascertain if checking these molecule levels might be more effective than monitoring protein levels to predict kidney disease in lupus patients. "The ability to detect these molecules in urine could potentially have tremendous impact on clinical diagnostics. Not only is urine a convenient body fluid to procure; in some clinical settings it may be the only fluid available,” Dr Mohan added.


Related Links:
University of Texas Southwestern Medical Center

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Immunofluorescence Analyzer
IFA System
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.